Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents
Article in Expert Review of Neurotherapeutics (March 2024)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Case Studies: Stahl's Essential Psychopharmacology
Monograph (November 2023)
Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree®): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder
Article in Brain and Behavior (February 2023)